Itors of Env gp120. ChemMedChem 2011, 6(8):1335?339. 1318. Matthias LJ, Yam PT, Jiang XM
Itors of Env gp120. ChemMedChem 2011, 6(8):1335?339. 1318. Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, Poumbourios P, Donoghue N, Hogg PJ: Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 2002, 3(8):727?32. Ryser HJ, Levy EM, Mandel R, DiSciullo GJ: Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 1994, 91(10):4559?563. Hogg PJ: Disulfide bonds as switches for protein function. Trends Biochem Sci 2003, 28(4):210?14. Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, et al: In vivo gp41 antibodies targeting the 2 F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009, 83(8):3617?625. Wild C, Greenwell T, Matthews T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9(11):1051?053. Covens K, Megens S, Dekeersmaeker N, Kabeya K, Balzarini J, De Wit S, Vandamme AM, Van Laethem K: The rare HIV-1 gp41 mutations 43 T and 50 V Fruquintinib supplement elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res 2010, 86(3):253?60. Wood MP, Cole PubMed ID: AL, Ruchala P, Waring AJ, Rohan LC, Marx P, Tarwater PM, Gupta P, Cole AM: A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. PubMed ID: PloS One 2013, 8(2):e55478. Sullivan N, Sun Y, Binley J, Lee J, Barbas CF 3rd, Parren PW, Burton DR, Sodroski J: Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998, 72(8):6332?338. Schon A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB 3rd, Sodroski J, Freire E: Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006, 45(36):10973?0980. Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, Lewis G, Paull J, Profy A, Ptak RG, Buckheit RW Jr, et al: Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008, 52(5):1768?781. Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA: Hepatitis C virus NS5A anchor53. disrupts human immunodeficiency virus. Proc Natl Acad Sci USA 2008, 105(14):5525?530. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, et al: MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011, 208(3):439?54. Thali M, Furman C, Helseth E, Repke H, Sodroski J: Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992, 66(9):5516?524. Moore JP, McKeating JA, Weiss RA, Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250(4984):1139?142. Morton TA, Bennett DB, Appelbaum ER, Cusimano DM, Johanson KO, Matico RE, Young PR, Doyle M, Chaiken IM: Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor.

Leave a Reply